Workflow
爱康国宾“漏诊”成罗生门
Bei Jing Shang Bao·2025-07-30 16:40

Core Viewpoint - Aikang Group held a media briefing on July 30 to address the controversy surrounding Ms. Zhang's ten-year health check-up, denying allegations of misdiagnosis and announcing a formal lawsuit against her for defamation [1][8]. Group 1: Company Response - Aikang Group refuted claims of flaws in Ms. Zhang's kidney examinations and denied any misdiagnosis or missed diagnosis allegations [1]. - The company has filed a lawsuit against Ms. Zhang, which has been accepted by the court [1][8]. - Aikang Group's Vice President, Wang Chaohui, emphasized that early diagnosis of kidney cancer relies more on imaging techniques (CT/MRI) rather than blood tests, clarifying that carcinoembryonic antigen (CEA) is not relevant for kidney cancer screening [3][4]. Group 2: Medical Procedures and Standards - Aikang Group explained that blood samples for serum tests are typically preserved for 1-7 days, making it impossible to provide ten years' worth of blood samples as requested by Ms. Zhang [4]. - The company has submitted all relevant data, including ten years of test reports and quality control results, to the regulatory authorities [4]. - All medical personnel are certified, and the equipment used complies with national regulations, ensuring that the testing process adheres to strict quality control standards [4][7]. Group 3: Clarification on Health Check-ups - Aikang Group's CEO, Zhang Ligang, stated that health check-ups are not equivalent to medical diagnoses, highlighting the differences in service models [6][7]. - The purpose of health check-ups is to identify potential health risks, while definitive diagnoses and treatments are conducted by specialized doctors [6][7]. - The public often misunderstands the boundaries between health check-ups and medical consultations, which can lead to unrealistic expectations regarding the capabilities of routine check-ups [6][7]. Group 4: Ms. Zhang's Claims - Ms. Zhang alleged that her ten-year health check-ups at Aikang Group did not detect any cancer risks, despite her reports indicating abnormalities in 2023 [8][9]. - She was diagnosed with kidney cancer in 2024, which had already progressed to a late stage by the time of detection [5][9]. - Ms. Zhang believes that the alleged misdiagnosis and oversight by Aikang Group contributed to the delay in her treatment [9].